Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$22.99 – $31.82
36% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.12B | $19.48B | $19.54B | $17.16B | $17.83B | $18.17B | $18.02B | $17.83B |
| Cost of revenue | $9.57B | $10.61B | $10.75B | $9.99B | $10.63B | $10.72B | $10.25B | $9.77B |
| Gross profit | $8.55B | $8.88B | $8.78B | $7.17B | $7.19B | $7.45B | $7.77B | $8.05B |
| Gross margin | 47.2% | 45.6% | 45.0% | 41.8% | 40.4% | 41.0% | 43.1% | 45.2% |
| R&D | $1.76B | $1.88B | $1.92B | $1.81B | $2.09B | $1.89B | $1.75B | $1.70B |
| Operating income | $1.72B | $1.64B | $1.54B | $553.0M | −$1.53B | −$115.0M | $529.0M | $1.65B |
| EBITDA | $2.79B | $2.81B | $2.85B | $2.00B | $115.0M | $1.04B | $2.33B | $2.65B |
| Net income | $1.09B | $1.17B | $1.19B | $3.32B | −$1.61B | −$466.0M | −$702.0M | $895.7M |
| Net margin | 6.0% | 6.0% | 6.1% | 19.3% | -9.0% | -2.6% | -3.9% | 5.0% |
| EPS (diluted) | 1.09 | 1.20 | 1.23 | 3.49 | -1.68 | -0.50 | -0.75 | 0.93 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $17.8B | $1.53 | $1.50–$1.68 | 1 |
| 2027 | $18.6B | $1.70 | $1.66–$1.86 | 1 |
| 2028 | $19.4B | $1.89 | $1.85–$2.07 | 1 |
| 2029 | $20.3B | $2.00 | $1.95–$2.19 | 1 |
Forward consensus · source: Financial Modeling Prep
ROYAL PHILLIPS NV ORD
No one on the platform currently holds RYLPF.
No tracked institution reports a position in RYLPF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-13 | $0.8500 | 2026-06-03 |
| 2025-05-13 | $0.8500 | 2025-06-06 |
| Execution date | Ratio |
|---|---|
| 2026-05-13 | 27.9341-for-26.9341 |
| 2025-05-13 | 24.6353-for-23.6353 |
| 2024-05-09 | 30.2684-for-29.2684 |
| 2023-05-11 | 23.3906-for-22.3906 |
| 2020-06-30 | 50.2971-for-49.2971 |
No one on the platform has traded RYLPF yet.
| -1.70% |
| $35.3B |
| — |
| SDMHFSartorius Stedim Biotech S.A. | $200.02 | +0.19% | $19.5B | — |
| SDZNYSandoz Group AG | $90.49 | -0.60% | $39.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Trading at 1.3× sales vs its 1.2× historical median P/S.
Fair value ≈ $23.07 · price $26.19 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.